Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 2
2021 4
2022 5
2023 5
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Druggable genomic landscapes of high-grade gliomas.
Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J; Johns Hopkins Molecular Tumor Board Investigators; Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Ghanem P, et al. Front Med (Lausanne). 2023 Dec 8;10:1254955. doi: 10.3389/fmed.2023.1254955. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38143440 Free PMC article.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski LA, Murray JC, Marrone KA, Scott SC, Houseknecht S, Falcon CJ, Evans P, Feliciano J, Hann CL, Ettinger DS, Smith KN, Anagnostou V, Forde PM, Brahmer JR, Levy B, Drilon A, Lam VK. Nakazawa M, et al. Among authors: ghanem p. Cancer Res Commun. 2024 Mar 14;4(3):786-795. doi: 10.1158/2767-9764.CRC-24-0065. Cancer Res Commun. 2024. PMID: 38407352 Free PMC article.
Precision Oncology Core Data Model to Support Clinical Genomics Decision Making.
Botsis T, Murray JC, Ghanem P, Balan A, Kernagis A, Hardart K, He T, Spiker J, Kreimeyer K, Tao J, Baras AS, Yegnasubramanian S, Canzoniero J, Anagnostou V; Johns Hopkins Molecular Tumor Board Investigators. Botsis T, et al. Among authors: ghanem p. JCO Clin Cancer Inform. 2023 Apr;7:e2200108. doi: 10.1200/CCI.22.00108. JCO Clin Cancer Inform. 2023. PMID: 37040583 Free PMC article.
Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.
Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, Lenoue-Newton ML, Rizvi HA, White JR, Baras AS, Anaya J, Landon BV, Majcherska-Agrawal M, Ghanem P, Lee J, Raskin L, Park AS, Tu H, Hsu H, Arbour KC, Awad MM, Riely GJ, Lovly CM, Anagnostou V. Scharpf RB, et al. Among authors: ghanem p. Cancer Res. 2022 Nov 2;82(21):4058-4078. doi: 10.1158/0008-5472.CAN-22-1731. Cancer Res. 2022. PMID: 36074020 Free PMC article.
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
Fatteh M, Wehr J, Karaindrou K, Xian RR, Gocke C, Lin MT, Petry D, Visvanathan K, Couzi R, Santa Maria C, Stearns V, Tao JJ, Anagnostou V, Canzoniero JV; and the Johns Hopkins Molecular Tumor Board; Johns Hopkins Molecular Tumor Board. Fatteh M, et al. JCO Precis Oncol. 2024 Oct;8:e2400254. doi: 10.1200/PO.24.00254. Epub 2024 Oct 11. JCO Precis Oncol. 2024. PMID: 39393037 Free PMC article.
17 results